10 Nov 2021
Posted in Medical Devices
ICP monitoring devices market in Asia-Pacific region to witness 7% growth through 2030, forecasts GlobalData
The intracranial pressure (ICP) monitoring devices market in Asia-Pacific (APAC) is expected to grow at a compound annual growth rate (CAGR) of 7% between 2021 and 2030, driven by the increase in the incidence of hydrocephalus and other neurological disorders and increase in traumatic brain injuries. As the elderly population increases, the chances of traumatic brain injury, intraventricular hemorrhage, infection, and neurodegenerative diseases also increase resulting in growing demand for ICP monitoring, forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘ICP Monitoring Devices (Neurology Devices) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)’, reveals that Integra Lifesciences, Medtronic Plc and Natus Medical Incorporated are the major players and together account for more than 60% of the APAC market in 2021.
Anusha Kaushik, Medical Devices Analyst at GlobalData, comments: “The market in APAC is mainly driven by the burden of patients with neurological diseases such as congenital and acquired hydrocephalus, brain tumor, and cysts. Countries such as China and Japan are investing in national programs to improve their understanding of disorders associated with the brain. The most preferred technique for ICP monitoring is external ventricular drainage (EVD).”
EVDs are considered the gold standard for ICP monitoring because of cost-effectiveness and their additional function of cerebrospinal drainage. Micro transducer devices are expensive and cannot be measured after implantation but are used when implantation of EVD is not possible and they have a lower risk of infection.
The demand for EVD will increase in the coming years as they are more familiar to surgeons, less expensive, and provide better clinical outcomes. As positive results come through clinical trials, the demand for antimicrobial EVD will increase as they offer a lower risk of infection in comparison with regular EVD and micro transducers.
Ms. Kaushik concludes: “Elevated levels of ICP have a bad impact on patients’ health. ICP monitoring helps in the detection of brain damage and helps in proper and effective treatment. As COVID-19 cases subside and vaccination of the general population continues, the backlog of elective procedure volumes for neurovascular surgeries are expected to recover by the end of 2021.”